Keyword Connections

sorafenib

Journals

4

1 Scientific reports

2 international immunopharmacology

3 journal of materials chemistry b

4 Pharmaceutical research

Research Groups

0

No Research Group Connected

Bibliographies

38

1 treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis

2 first- and second-line targeted systemic therapy in hepatocellular carcinoma—an update on patient selection and response evaluation

3 yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma

4 effect of itraconazole on the cornea in a murine suture model and penetrating keratoplasty model

5 a comparative study of sorafenib and metronomic chemotherapy for barcelona clinic liver cancer-stage c hepatocellular carcinoma with poor liver function

6 metastatic renal cell carcinoma: a guide to therapy based on current evidence

7 a combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer

8 receptor-targeted, drug-loaded, functionalized graphene oxides for chemotherapy and photothermal therapy

9 Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma

10 Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)

11 Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions

12 Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib

13 Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives

14 Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma

15 Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)

16 Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions

17 Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib

18 Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives

19 KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program

20 Sorafenib attenuated the function of natural killer cells infiltrated in HCC through inhibiting ERK1/2.

21 Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a And Sorafenib in Liver Cancers.

22 Efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: a comparative retrospective study

23 Correction for: The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells.

24 Ibrutinib potentiates anti-hepatocarcinogenic efficacy of sorafenib by targeting EGFR in tumor cells and BTK in immune cells in the stroma.

25 Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study.

26 radiation recall dermatitis in patients treated with sorafenib

27 feasibility of 4d perfusion ct imaging for the assessment of liver treatment response following sbrt and sorafenib

28 selective and irreversible induction of necroptotic cell death in lung tumorspheres by short-term exposure to verapamil in combination with sorafenib

29 development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic uft chemotherapy

30 triclosan treatment decreased the antitumor effect of sorafenib on hepatocellular carcinoma cells

31 sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (nash) rodent model

32 factors associated with post-progression survival in patients with advanced hepatocellular carcinoma treated with sorafenib

33 antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-kit exon 13 missense mutation k642e

34 successful treatment of paraganglioma with sorafenib: a case report and brief review of the literature

35 postoperative adjuvant sorafenib or sunitinib for nonmetastatic renal cell carcinoma with venous tumor thrombus: a prospective cohort study

36 study of rna interference targeting net-1 combination with sorafenib for hepatocellular carcinoma therapy in vitro and in vivo

37 Corrigendum to “Dose-dependent regulation of mitochondrial function and cell death pathway by sorafenib in liver cancer cells” [Biochem. Pharmacol. 176 (2020) 113902] (Biochemical Pharmacology (2020) 176, (S0006295220301301), (10.1016/j.bcp.2020.113902))

38 Prediction of Toxicities Induced by Sorafenib and Regorafenib